Skip to main content
Retour
ERAS logo

Erasca, Inc.

Qualité des données : 100%
ERAS
NASDAQ Healthcare Biotechnology
14,67 €
▲ 0,35 € (2,44%)
Cap. Boursière : 4,56B
Fourchette du Jour
13,86 € 14,94 €
Fourchette 52 Semaines
1,01 € 16,41 €
Volume
3 948 761
Moyenne 50J / 200J
11,98 € / 4,61 €
Clôture Précédente
14,32 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -36,6 0,3
P/B 14,0 2,9
ROE % -33,3 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
11,60 € -20.9%
Low: 5,00 € High: 20,00 €
BPA Prévisionnel
-0,43 €
CA Est.
7,5 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 -0,40 €
-0,40 € – -0,40 €
300 M 2
FY2029 -0,77 €
-0,77 € – -0,77 €
35 M 4
FY2028 -0,66 €
-0,91 € – -0,50 €
3,7 M 6

Points Clés

Debt/Equity of 0,14 — conservative balance sheet
Negative free cash flow of -95,58M
PEG of 0,23 suggests growth is underpriced

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-33,27%
ROIC-26,47%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,14
Current Ratio10,04
Interest Coverage0,00

Valorisation

P/E Ratio
-36,61
P/B Ratio14,02
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -124,55M
ROE -33,27% ROA -31,44%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -95,58M
ROIC -26,47% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,14 Current Ratio 10,04
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -36,61 P/B Ratio 14,02
P/S Ratio N/A PEG Ratio 0,23
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 4,56B Enterprise Value 4,53B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -124,55M -161,65M -125,04M -242,81M -122,76M
EPS (Diluted) -0,44 -0,69 -0,83 -1,99 -1,03
Gross Profit -3,11M 0,0 -3,73M -2,64M -829 000,0
Operating Income -131,41M -179,59M -141,53M -247,45M -124,88M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 396,15M 502,53M 395,30M 514,91M 501,42M
Total Liabilities 70,98M 79,03M 78,61M 103,06M 44,89M
Shareholders' Equity 325,17M 423,50M 316,69M 411,85M 456,53M
Total Debt 47,14M 51,89M 55,86M 55,10M 18,79M
Cash & Equivalents 73,81M 67,74M 93,08M 284,22M 360,49M
Current Assets 286,24M 308,79M 320,68M 444,50M 420,02M
Current Liabilities 28,51M 31,40M 26,16M 48,69M 26,22M